Anti-Rheumatic Drugs - Brazil

Brazil

The Anti-Rheumatic Drugs market in Brazil is expected to achieve a revenue of €0.47bn in the year 2024.
It is projected to witness an annual growth rate (CAGR 2024-2029) of 1.25%, leading to a market volume of €0.50bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €32,180.00m in 2024.
Brazil's growing pharmaceutical industry is driving increased demand for anti-rheumatic drugs, with local manufacturers expanding their product offerings to meet the needs of the country's aging population.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Brazil is a rapidly growing market that has been gaining momentum in recent years.

Customer preferences: Brazilian customers have been showing a growing preference for Anti-Rheumatic Drugs due to the increasing incidence of rheumatoid arthritis and other autoimmune diseases. Additionally, the aging population in Brazil has also contributed to the growth in demand for Anti-Rheumatic Drugs.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Brazil is the increasing use of biologic drugs. Biologic drugs have been gaining popularity due to their effectiveness in treating autoimmune diseases. Additionally, the introduction of biosimilars has also contributed to the growth of the Anti-Rheumatic Drugs market in Brazil. Biosimilars are cheaper alternatives to biologic drugs and have been gaining popularity due to their affordability.

Local special circumstances: Brazil has a unique healthcare system that has contributed to the growth of the Anti-Rheumatic Drugs market. The Brazilian government has been providing free Anti-Rheumatic Drugs to patients through the public healthcare system. This has increased the accessibility of Anti-Rheumatic Drugs to patients who may not have been able to afford them otherwise.

Underlying macroeconomic factors: The Brazilian economy has been growing steadily in recent years, which has contributed to the growth of the Anti-Rheumatic Drugs market. Additionally, the Brazilian government has been investing heavily in the healthcare sector, which has also contributed to the growth of the Anti-Rheumatic Drugs market. The increasing prevalence of autoimmune diseases in Brazil has also been a major driver of the growth in the Anti-Rheumatic Drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.